# RenovoRx, Inc.: overview

RNXT · Nasdaq · CIK 1574094 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/rnxt.md) · [Financials](/companies/rnxt/financials.md) · [Filings](/companies/rnxt/filings.md) · [Insiders](/companies/rnxt/insiders.md)

Latest reported revenue: [$909.0k](/filings/0001193125-26-349190.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 13, 2026 (XBRL us-gaap:Revenues, accession 0001193125-26-349190).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | not reported | not reported | [197](/filings/0001193125-26-224100.md) | [422](/filings/0001193125-26-349190.md) | [266](/filings/0001493152-25-022304.md) | [238 d](/filings/0001193125-26-131928.md) | [563](/filings/0001193125-26-224100.md) | [909](/filings/0001193125-26-349190.md) |
| Gross margin | % | not reported | not reported | [52.3%](/filings/0001193125-26-224100.md) | [64.0%](/filings/0001193125-26-349190.md) | [80.1%](/filings/0001493152-25-022304.md) | [88.2% d](/filings/0001193125-26-131928.md) | [85.1%](/filings/0001193125-26-224100.md) | [84.3%](/filings/0001193125-26-349190.md) |
| Operating margin | % | not reported | not reported | [(1578.7%)](/filings/0001193125-26-224100.md) | [(634.6%)](/filings/0001193125-26-349190.md) | [(1203.0%)](/filings/0001493152-25-022304.md) | [(1479.8%) d](/filings/0001193125-26-131928.md) | [(616.2%)](/filings/0001193125-26-224100.md) | [(368.4%)](/filings/0001193125-26-349190.md) |
| Net margin | % | not reported | not reported | [(1228.4%)](/filings/0001193125-26-349190.md) | [(686.0%)](/filings/0001193125-26-349190.md) | [(1094.7%)](/filings/0001493152-25-022304.md) | [(1235.7%) d](/filings/0001193125-26-131928.md) | [(625.4%)](/filings/0001193125-26-349190.md) | [(320.2%)](/filings/0001193125-26-349190.md) |
| Diluted EPS | $ per share | [(0.10)](/filings/0001493152-25-022304.md) | not reported | [(0.08)](/filings/0001193125-26-224100.md) | [(0.08)](/filings/0001193125-26-349190.md) | [(0.08)](/filings/0001493152-25-022304.md) | not reported | [(0.09)](/filings/0001193125-26-224100.md) | [(0.06)](/filings/0001193125-26-349190.md) |
| Free cash flow | $k | not reported | not reported | [(3,383)](/filings/0001193125-26-224100.md) | [(2,302) d](/filings/0001193125-26-349190.md) | [(2,270) d](/filings/0001493152-25-022304.md) | [(3,020) d](/filings/0001193125-26-131928.md) | [(3,709)](/filings/0001193125-26-224100.md) | [(2,938) d](/filings/0001193125-26-349190.md) |

- Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | [0.0](/filings/0001193125-26-131928.md) | [1.1](/filings/0001193125-26-131928.md) |
| Gross margin | % | not reported | not reported | not reported | [100.0%](/filings/0001193125-26-131928.md) | [70.9%](/filings/0001193125-26-131928.md) |
| Operating margin | % | not reported | not reported | not reported | [(25511.6%)](/filings/0001193125-26-131928.md) | [(1114.0%)](/filings/0001193125-26-131928.md) |
| Net margin | % | not reported | not reported | not reported | [(20497.7%)](/filings/0001193125-26-131928.md) | [(994.5%)](/filings/0001193125-26-131928.md) |
| Diluted EPS | $ per share | [(1.21)](/filings/0001493152-22-008080.md) | [(1.09)](/filings/0001493152-24-012357.md) | [(0.99)](/filings/0001641172-25-001932.md) | [(0.40)](/filings/0001193125-26-131928.md) | [(0.32)](/filings/0001193125-26-131928.md) |
| Free cash flow | $m | not reported | not reported | not reported | [(9.1)](/filings/0001193125-26-131928.md) | [(11.0)](/filings/0001193125-26-131928.md) |

- Revenue. XBRL Revenue: us-gaap:Revenues.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareBasicAndDiluted; Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/rnxt/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [AIGH Capital Management LLC](/funds/1835943.md) | 2026-06-30 | $4.3m | 4,405,439 |  | Added +699,242 |
| [Bleichroeder LP](/funds/1781002.md) | 2026-06-30 | $1.6m | 1,666,098 |  | Unchanged |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $1.4m | 1,443,742 |  | Reduced −3,435 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $415.7k | 424,148 |  | Added +42,425 |
| [Wealthspire Advisors, LLC](/funds/1646247.md) | 2026-06-30 | $247.5k | 252,525 |  | Unchanged |
| [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $235.5k | 240,330 |  | Added +82,428 |
| [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $130.9k | 133,597 |  | Reduced −99,087 |
| [NORTHERN TRUST CORP](/funds/73124.md) | 2026-06-30 | $83.5k | 85,207 |  | Added +43,046 |
| [Chicago Partners Investment Group LLC](/funds/1563525.md) | 2026-06-30 | $78.9k | 92,356 |  | Unchanged |
| [NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO](/funds/1141802.md) | 2026-06-30 | $73.1k | 74,596 |  | Reduced −24,864 |

## Recent filings

[All 289 filings](/companies/rnxt/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-08-20 | 20:05 ET | [8-K](/filings/0001493152-26-039472.md) | 8.01 Other events | 0001493152-26-039472 |
| 2026-08-13 | 20:11 ET | [10-Q](/filings/0001193125-26-349190.md) | Quarterly report, period 2026-06-30 | 0001193125-26-349190 |
| 2026-08-13 | 20:06 ET | [8-K/A](/filings/0001193125-26-349157.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-349157 |
| 2026-08-12 | 20:16 ET | [8-K](/filings/0001193125-26-346894.md) | 9.01 Financial statements and exhibits | 0001193125-26-346894 |
| 2026-08-04 | 20:10 ET | [8-K](/filings/0001493152-26-035995.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-26-035995 |
| 2026-07-02 | 12:30 ET | [8-K](/filings/0001493152-26-031662.md) | 3.01 Delisting notice | 0001493152-26-031662 |
| 2026-06-30 | 20:55 ET | [8-K](/filings/0001493152-26-031303.md) | 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001493152-26-031303 |
| 2026-05-15 | 21:25 ET | [10-K/A](/filings/0001193125-26-227256.md) | Annual report, amended, period 2025-12-31 | 0001193125-26-227256 |
| 2026-05-14 | 20:19 ET | [10-Q](/filings/0001193125-26-224100.md) | Quarterly report, period 2026-03-31 | 0001193125-26-224100 |
| 2026-05-14 | 20:17 ET | [8-K](/filings/0001193125-26-224080.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-224080 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-131928.md), filed Mar 30, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/03d3a4d3-6e32-4b8c-91f0-e4480333d30a)

## About the filer

- CIK: 1574094
- Tickers: RNXT
- Exchange: Nasdaq
- SIC code: 3841 Surgical & Medical Instruments & Apparatus
- State of incorporation: DE
- Filer category: <br>Emerging growth company

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:43 ET. No prices; not investment advice.